Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Eli Lilly and Company

Key Points
Eli Lilly's performance over the past year hasn't been as strong as usual.
The company's growth prospects justify its higher-than-average valuation.
Lilly is also a terrific dividend stock.
Eli Lilly (NYSE: LLY) has been on a tear for the better part of the last decade, but the company has experienced a bit of a slowdown of late. The stock is down 8% over the trailing-12-month period, partly because of a clinical setback, although general market volatility and the threat of tariffs probably didn't help.
However, this is little more than a temporary slump. Lilly's prospects remain incredibly bright, and at current levels, the company's shares even look undervalued.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Looking at (and beyond) valuation metrics
One might scoff at the idea that Eli Lilly is undervalued. The company is trading at 27 times forward earnings, which is well above the average of 17.5 for the healthcare industry.
However, that doesn't tell us the whole story. If Eli Lilly can grow its revenue and earnings much faster than the average over the next five years or so, then that would more than justify its premium. Note that the company has been doing precisely that over the past two years. In fact, Lilly's recent top-line growth is, frankly, abnormal for a pharmaceutical company of its size, especially considering it's kept it up over several quarters.
The only other pharmaceutical giant that has come close to Eli Lilly in this category is its longtime rival, Novo Nordisk, which it's now leaving in the dust. So, Lilly has proven it can beat the average in this category -- what about the future?
There's more to look forward to
Eli Lilly should benefit from significant tailwinds that will help it maintain strong sales growth over the next five years. The most important is the growth of the market for weight management medicines. Breakthroughs in the field, the growing population of overweight individuals over the past few decades, and the higher prevalence of a range of health conditions associated with that are all helping to fuel soaring demand for anti-obesity drugs.
Lilly is at the forefront of this wave. Its drug tirzepatide, sold under the brand name Zepbound in weight management, is beating records. Wall Street analysts were licking their chops when they modeled peak annual sales of $25 billion for the medicine a few years ago. That would have put tirzepatide in an exceedingly rare, elite category of therapies ever to reach a peak that high. However, tirzepatide could generate more than that this year (it racked up $14.7 billion in the first half of the year), after being approved only three years ago.
Some new projections now predict sales of almost $62 billion for tirzepatide by 2030. That would put it in a category of...one.
But tirzepatide won't be Eli Lilly's only growth driver. The company is inching closer to launching orforglipron, an oral GLP-1 medicine. This therapy aced late-stage clinical trials, some of which put it head-to-head against other notable drugs -- and orforglipron emerged the winner.
Orforglipron could address some crucial shortcomings. First, some patients prefer oral pills over needles. Second, pills are cheaper to manufacture, store, and transport. They are arguably more commercially viable than subcutaneous injection at the same efficacy. And while orforglipron didn't match tirzepatide's potency, it will likely end up being cheaper and a better option for patients paying out of pocket -- tirzepatide's price tag has been a significant turnoff for many.
By 2030, orforglipron could generate up to $12.7 billion in sales. Together with tirzepatide and other products, it could help make Lilly the world's top-selling pharmaceutical company by then. So Eli Lilly's growth outlook still looks strong. The drugmaker is more than reasonably valued relative to its growth potential.
Don't forget the dividend
There are plenty of other aspects of Eli Lilly's business that make the stock a buy. Let's focus on just one of them: its dividend program. Lilly has been generating plenty of cash and has used some of it to reward shareholders with consistent and material payout increases. Over the past five years, the company's dividend has doubled. And there's more where that came from -- the payout ratio of 37% still looks reasonable.
The stock may not have a particularly impressive forward yield. It's just 0.7%, which is lower than the S&P 500's already low average of 1.2%. However, every other aspect of its dividend profile looks great. Altogether, Eli Lilly is an excellent choice for both income- and growth-seeking investors.
Should you invest $1,000 in Eli Lilly right now?
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $590,287!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,173,807!*
Now, it’s worth noting Stock Advisor’s total average return is 1,047% — a market-crushing outperformance compared to 195% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
*Stock Advisor returns as of October 27, 2025
Prosper Junior Bakiny has positions in Eli Lilly, Johnson & Johnson, and Novo Nordisk. The Motley Fool has positions in and recommends AbbVie and Merck. The Motley Fool recommends Johnson & Johnson and Novo Nordisk. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

1 Undervalued Growth Stock Down 8% to Buy Before 2026

Williams' board of directors has approved a regular dividend of $0.50 per share, or $2.00 annualized, on the company's common stock, payable on Dec. 29, 2025, to holders of record at the close of business on Dec. 12, 2025. This is a 5.3% increase from Williams' 2024 quarterly dividend of $0.4750 per share. illiams has paid a common stock dividend every quarter since 1974.
The board of directors of Eli Lilly has declared a dividend for the fourth quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on December 10, 2025, to shareholders of record at the close of business on November 14, 2025.
Cheniere Energy today announced that its Board of Directors has declared a quarterly cash dividend of $0.555 per common share, an increase of over 10% from the prior quarter, payable on November 18, 2025 to shareholders of record as of the close of business on November 7, 2025.
Humana announced today that its Board of Directors has declared a cash dividend to stockholders of $0.885 per share payable on January 30, 2026 to stockholders of record as of the close of business on December 26, 2025.
The Board of Directors of Albemarle announced today that it declared a quarterly common stock dividend of $0.405 per share. The dividend, which has an annualized rate of $1.62, is payable January 2, 2026, to shareholders of record at the close of business as of December 12, 2025.
VIDEO: Daily Dividend Report: WMB,LLY,LNG,HUM,ALB
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Daily Dividend Report: WMB,LLY,LNG,HUM,ALB

An updated edition of the Sept. 8, 2025, article.
The global cancer treatment market is entering a transformative phase, driven by rising cancer incidence and rapid scientific progress. According to the American Cancer Society, the United States alone is projected to report 2.04 million new cancer cases and over 618,000 deaths in 2025. An aging population and lifestyle-related risks are increasing global cancer prevalence, pushing healthcare systems toward higher oncology spending.
Meanwhile, innovation is transforming the way cancer is managed. Advances in immunotherapies, targeted drugs and personalized vaccines have expanded options well beyond traditional chemotherapy and radiation. Immune-based approaches — such as checkpoint inhibitors, CAR-T therapies, therapeutic vaccines and oncolytic viruses — train the body’s own defenses to fight tumors. Targeted therapies focus on specific genetic mutations, improving precision and reducing side effects, while personalized cancer vaccines represent a major step forward in precision oncology.
Emerging technologies like genomic sequencing, artificial intelligence (AI) and machine learning (ML) are accelerating biomarker discovery, refining patient selection, and improving early detection. Though a universal cure remains elusive, survival rates and the quality of life continue to improve across many cancer types, reflecting both scientific advances and earlier diagnosis.
Pharmaceutical companies are responding with aggressive investment. Global leaders — including Novartis, AstraZeneca, J&J, Pfizer PFE, AbbVie ABBV, Merck MRK, Bristol Myers Squibb and Eli Lilly LLY — are expanding their pipelines in antibody-drug conjugates (ADCs), bispecific antibodies, and next-generation immuno-oncology agents. Smaller biotech firms remain key sources of innovation, driving new collaborations, licensing deals and acquisitions as larger players seek novel assets with best-in-class potential.
Continued innovation, favorable reimbursement trends and expanding treatment options position the oncology segment as one of the most attractive and resilient areas for long-term investors.
With our thematic screens, you can easily spot stocks tied to trends shaping the future of investing. If the cancer space appeals to you and you’re looking to align your portfolio with this rising trend, now might be the time to consider stocks like Relay Therapeutics RLAY, Fate Therapeutics FATE and Verastem Oncology VSTM.
Explore 36 cutting-edge investment themes with Zacks Thematic Investing Screens and uncover your next big opportunity.
3 Cancer Stocks in Focus
Relay Therapeutics is developing RLY-2608, its lead investigational candidate and a mutant-selective PI3Kα inhibitor, as a novel medicine for CDK4/6-experienced patients with PI3Kα mutations, where there is a large unmet medical need. In clinical studies, RLY-2608 has shown the potential benefit in improving both the tolerability profile and progression-free survival compared to standard-of-care drugs in this setting. Relay initiated a pivotal phase III study called ReDiscover-2 on RLY-260, in combination with AstraZeneca’s Faslodex for second-line PI3Kα-mutated, HR+/HER2- advanced breast cancer in the second quarter.
The company is also making progress in its development plans for investigational triplet combinations, which it believes can allow RLY-2608 to address patients in earlier settings.
Relay Therapeutics is also rapidly progressing with the development of other front-line breast cancer regimens while planning for the development of future oral endocrine therapy combinations.
Relay Therapeutics has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Fate Therapeutics is focused on developing and manufacturing universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. Its immuno-oncology pipeline includes iPSC-derived natural killer cells and T-cell product candidates.
Fate Therapeutics is co-developing FT825/ONO-8250, a multiplexed-engineered, iPSC-derived CAR T-cell product candidate, with ONO Pharmaceutical. It is conducting a phase I study to assess the safety, pharmacokinetics and activity of FT825/ONO-8250 in patients with advanced solid tumors.
To date, treatment with FT825/ONO-8250 has shown a favorable safety profile with no dose-limiting toxicities. Fate Therapeutics also has some next-generation iPSC-derived CAR T-cell programs in pre-clinical development. In July, the FDA allowed the company’s investigational new drug (IND) application to begin phase I clinical studies on FT836, its MICA/B-targeted CAR T-cell program. Fate has a Zacks Rank of 2.
Verastem Oncology’s novel combination regimen of avutometinib plus defactinib was approved by the FDA in early May for treating KRAS mutant recurrent low-grade serous ovarian cancer (LGSOC), a rare and distinct type of ovarian cancer. The approval was granted under the FDA’s accelerated approval pathway and is commercialized in the U.S. market as an oral combination co-pack with the two prescription products, known as “Avmapki Fakzynja Co-Pack.” The innovative combination therapy generated $2.1 million in sales in the first six weeks of launch.
Following the FDA approval, Avmapki Fakzynja Co-Pack is the first and only FDA-approved treatment for the LGSOC indication. Per Verastem Oncology, the combo sets a new standard of care for women with recurrent LGSOC with a KRAS mutation.
The company is also evaluating avutometinib plus defactinib in combination studies in first-line metastatic pancreatic cancer as well as non-small cell lung cancer in early to mid-stage studies. In May, VSTM reported strong overall response rates from a phase I/II study evaluating avutometinib plus defactinib in combination with chemotherapy for the first-line treatment of metastatic pancreatic ductal adenocarcinoma (PDAC). Based on the positive data, VSTM plans to initiate a registrational phase III study in front-line metastatic PDAC in 2026.
This Zacks Rank #2 company also recently announced positive preliminary data from an early-stage study for VS-7375, its KRAS G12D (ON/OFF) inhibitor in patients with KRAS G12D mutant solid tumors.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

3 Cancer-Focused Stocks Showing Strong Pipeline Progress

Incyte Corporation INCY reported third-quarter 2025 adjusted earnings of $2.26 per share, which beat the Zacks Consensus Estimate of $1.66. The company had incurred adjusted earnings of $1.07 per share in the year-ago quarter.
Total revenues in the third quarter were $1.37 billion, which grew 20% year over year, driven primarily by the sustained performance of its lead drug, Jakafi (ruxolitinib), and increased sales of Opzelura (ruxolitinib) cream on strong launch and demand. The top line beat the Zacks Consensus Estimate of $1.26 billion.
All percentages mentioned below are on a reported basis.
INCY's Q3 Results in Detail
Revenues from the sale of Jakafi, a first-in-class JAK1/JAK2 inhibitor approved for polycythemia vera, myelofibrosis and refractory acute graft-versus-host disease (GVHD), came in at $791.1 million, up 7% from the year-ago quarter, owing to a 10% increase in paid demand. Jakafi's sales beat the Zacks Consensus Estimate of $770 million.
Opzelura (ruxolitinib) cream, approved for atopic dermatitis and vitiligo, generated $188 million in sales, which rose 35% year over year, and beat the Zacks Consensus Estimate of $179.1 million. The year-over-year rise in sales was driven by increased patient demand and refills in the United States for both its approved indications.
The newly approved medicine Zynyz (retifanlimab-dlwr) generated sales of $22.7 million, which significantly increased from the year-ago quarter and beat the Zacks Consensus Estimate of $9.5 million. The company obtained accelerated approval for Zynyz to treat metastatic or recurrent locally advanced Merkel cell carcinoma. Net product revenues of Iclusig were $37.6 million, up 26% year over year. The figure beat the Zacks Consensus Estimate of $30.6 million. Pemazyre generated $22.7 million in sales, reflecting a year-over-year increase of 10%. The figure also surpassed the Zacks Consensus Estimate of $22 million.
Minjuvi's revenues totaled $42 million, up 34% year over year. The figure also beat the Zacks Consensus Estimate of $37.9 million. Incyte gained worldwide exclusive global rights for tafasitamab from MorphoSys AG, which is marketed as Monjuvi in the United States and as Minjuvi in the ex-U.S. markets in 2024.
Incyte and partner Syndax Pharmaceuticals obtained FDA approval for axatilimab-csfr, an anti-CSF-1R antibody, for the treatment of GVHD after the failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg. The candidate was approved under the brand name Niktimvo. The drug is Incyte’s second approved treatment for chronic GVHD (third-line) and was launched in the United States during the first quarter of 2025. The drug recorded $45.8 million in sales in the third quarter of 2025, up 27% sequentially, driven by strong uptake.
Shares of Incyte have gained 34.8% year to date compared with the industry’s 10.3% growth.
Image Source: Zacks Investment Research
Jakafi is marketed by Incyte in the United States and by Novartis NVS as Jakavi in ex-U.S. markets. Jakavi royalty revenues from Novartis for commercialization in ex-U.S. markets rose 9% to $125.6 million. Jakavi royalties beat the Zacks Consensus Estimate of $119.2 million.
Incyte also receives royalties from the sales of Tabrecta (capmatinib) for the treatment of adult patients with metastatic non-small-cell lung cancer. Its partner, Novartis, has exclusive worldwide development and commercialization rights for Tabrecta. Royalty revenues from the drug’s sales amounted to $6.5 million, up 10% year over year. However, the reported figure missed the Zacks Consensus Estimate of $7.2 million.
Olumiant’s (baricitinib) product royalty revenues from Eli Lilly LLY totaled $37.1 million, up 7% year over year. The figure marginally missed the Zacks Consensus Estimate of $37.2 million. Incyte has a collaboration agreement with Eli Lilly for Olumiant. The drug is a once-daily oral JAK inhibitor discovered by Incyte and licensed to LLY. It is approved for several types of autoimmune diseases.
Adjusted research and development (R&D) expenses totaled $467 million, down 11% year over year. This decrease was primarily due to a $100 million milestone payment made to MacroGenics in the year-ago quarter. Excluding the upfront and milestone payments and Escient severance payments from the year-ago period, R&D expenses increased 7% in third-quarter 2025, primarily driven by continued investment in late-stage development assets.
Adjusted selling, general and administrative (SG&A) expenses were $308 million, up 11% from the prior-year quarter’s number, primarily due to increased international marketing activities to support product launches.
INCY’s cash, cash equivalents and marketable securities amounted to $2.9 billion as of Sept. 30, 2025, compared with the $2.4 billion recorded as of June 30, 2025.
Incyte Corporation Price, Consensus and EPS Surprise
INCY Updates 2025 Guidance
The company now expects Jakafi revenues for 2025 in the range of $3.05-$3.075 billion compared with the previously reported band of $3-$3.05 billion. Opzelura net product revenues are expected to remain unchanged in the band of $630-$670 million in 2025.
Adjusted R&D expenses and adjusted SG&A expenses are expected to remain unchanged in the ranges of $1.815-$1.84 billion and $1.16-$1.185 billion, respectively, in 2025.
INCY's Zacks Rank & Stock to Consider
Incyte currently carries a Zacks Rank #3 (Hold).
A better-ranked stock in the overall medical sector is ANI Pharmaceuticals ANIP, carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2025 earnings per share have risen from $7.25 to $7.29. During the same period, earnings per share for 2026 have increased from $7.74 to $7.81. Year to date, ANIP’s shares have rallied 68%.
ANI Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with an average surprise of 22.66%.
Quantum Computing Stocks Set To Soar
Artificial intelligence has already reshaped the investment landscape, and its convergence with quantum computing could lead to the most significant wealth-building opportunities of our time.
Today, you have a chance to position your portfolio at the forefront of this technological revolution. In our urgent special report, Beyond AI: The Quantum Leap in Computing Power, you'll discover the little-known stocks we believe will win the quantum computing race and deliver massive gains to early investors.
Access the Report Free Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

INCY's Q3 Earnings & Revenues Beat Estimates on Higher Product Sales

A look at the weighted underlying holdings of the Roundhill GLP-1 & Weight Loss ETF (OZEM) shows an impressive 15.9% of holdings on a weighted basis have experienced insider buying within the past six months.
Eli Lilly (Symbol: LLY), which makes up 15.90% of the Roundhill GLP-1 & Weight Loss ETF (OZEM), has seen 8 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $5,597,580 worth of LLY, making it the #2 largest holding. The table below details the recent insider buying activity observed at LLY:
LLY — last trade: $826.41 — Recent Insider Buys:
Also see:
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

15.9% of OZEM Holdings Seeing Recent Insider Buys

Key Points
BDF-GESTION sold 4,149 shares of Eli Lilly and Company; Transaction value was $3.1 million
Transaction represents 0.37% of BDF-GESTION's 13F reportable assets under management
Post-trade stake: 19,949 shares valued at $15.22 million as of September 30, 2025
Position now represents 1.8% of fund AUM, which places it outside the fund's top five holdings
What happened
According to a filing with the U.S. Securities and Exchange Commission published on Oct. 09, 2025, BDF-GESTION sold 4,149 shares of Eli Lilly (NYSE:LLY) stock during the quarter. The estimated transaction value was $3.09 million, using the average unadjusted closing price for the quarter. After the trade, the fund held 19,949 shares, worth $15.22 million at quarter end.
What else to know
BDF-GESTION reduced its stake in Eli Lilly and Company; the holding now accounts for 1.8% of the fund’s 13F AUM, down from 2.1% in the previous quarter
Top holdings after the filing:
NVDA: $89.5 million (10.7% of AUM) as of September 30, 2025
MSFT: $78.5 million (9.4% of AUM) as of September 30, 2025
AAPL: $75.5 million (9.0% of AUM) as of September 30, 2025
AVGO: $37.8 million (4.5% of AUM) as of September 30, 2025
META: $35.9 million (4.3% of AUM) as of September 30, 2025
As of October 8, 2025, shares were priced at $845.72, down 7.44% year-to-date through October 8, 2025 and underperformed the S&P 500 by 23.7 percentage points over the past year
Company Overview
Revenue (TTM)
$53.26 billion
Net Income (TTM)
$13.80 billion
Dividend Yield
0.68%
Price (as of market close 10/08/25)
$845.72
Company Snapshot
Eli Lilly and Company offers a broad portfolio of pharmaceuticals for diabetes, oncology, immunology, neuroscience, and other therapeutic areas; including Mounjaro, Zepbound, Taltz, and Verzenio.
Generates revenue primarily through the discovery, development, manufacturing, and global sale of branded prescription medicines, leveraging a robust pipeline and strategic collaborations.
With a focus on patients requiring innovative therapies for chronic and acute conditions.
Eli Lilly and Company is a global pharmaceutical leader with a diversified product lineup and a strong focus on research-driven innovation. The company's scale and established presence in key therapeutic categories support consistent revenue generation and competitive positioning. Strategic partnerships and a commitment to advancing new treatments underpin its long-term growth strategy.
Foolish take
BDF-Gestion's bet on Eli Lilly wasn't the biggest one it made in the third quarter, but it was significant. Valued at $15.2 million, it was the firm's eighth-largest holding at the end of September.
Lilly's dual GLP-1/GIP receptor agonist, tirzepatide, could become the top-selling drug of all time. First approved as Mounjaro for diabetes in 2022, and again as Zepbound for obesity in 2023, it's already a mega-blockbuster.
In the first half of 2025, combined sales of Zepbound and Mounjaro soared 121% to reach $14.7 billion. It's just one of dozens of treatments that Lilly markets, but it's already responsible for a majority of total revenue. Sales could soar even further. Estimates on Wall Street vary, but some analysts expect combined sales of tirzepatide and similar drugs to reach a whopping $100 billion annually by 2030.
Tirzepatide is an important revenue stream, but it isn’t the only growth driver in Eli Lilly’s product lineup. Sales of Ebglyss, a treatment for eczema, could soar going forward. Long-term trial data recently showed that it helped about 80% of patients achieve clearance on at least 75% of their bodies.
Glossary
13F reportable assets: Assets that institutional investment managers must disclose quarterly to the SEC, showing holdings in certain securities.
Assets under management (AUM): The total market value of investments managed by a fund or investment firm on behalf of clients.
Stake: The ownership interest or number of shares held in a company by an investor or fund.
Quarter: A three-month period used by companies and investors for financial reporting and performance measurement.
Filing: An official document submitted to a regulatory authority, often detailing financial or ownership information.
Top holdings: The largest investments in a fund's portfolio, typically ranked by market value.
Dividend yield: The annual dividend payment divided by the stock's price, expressed as a percentage.
Therapeutic areas: Categories of diseases or medical conditions targeted by a company's pharmaceutical products.
Pipeline: The set of drug candidates a pharmaceutical company is developing, from early research to late-stage trials.
Strategic collaborations: Partnerships between companies to jointly develop, market, or distribute products or technologies.
TTM: The 12-month period ending with the most recent quarterly report.
Where to invest $1,000 right now
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 1,033%* — a market-crushing outperformance compared to 193% for the S&P 500.
They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.
*Stock Advisor returns as of October 27, 2025
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Apple, Meta Platforms, Microsoft, and Nvidia. The Motley Fool recommends Broadcom and recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

BDF-GESTION Trims Its Eli Lilly (LLY) Stake by 4,149 Shares

Key Points
Anti-obesity drugs are being considered for a range of addictive behaviors.
Pfizer just acquired a next-generation, clinical-stage maker of obesity treatments.
What's the hottest trend in the pharmaceutical industry right now?
You could make a strong argument that it's the expansion of so-called GLP-1 medications. These miracle drugs effectively promote weight loss (in addition to treating diabetes), but there's growing evidence that they can also tame cravings for alcohol and narcotics, and even mitigate behaviors like sex addiction and gambling.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Right now, the major manufacturers of GLP-1 drugs are Novo Nordisk (NYSE: NVO), which makes Wegovy, and Eli Lilly (NYSE: LLY), which manufactures Zepbound. These are already blockbuster drugs, and they're bound to get even bigger. Demand for and sales of the weight loss drugs are only expected to accelerate, and the size of the anti-obesity drug market is forecast to hit $100 billion within five years.
A third major player
But a third major pharma player is emerging in the GLP-1 space.
That would be Pfizer (NYSE: PFE), which is now getting into the weight loss market. In September, it announced that it would acquire Metsera, a next-generation, clinical-stage biopharmaceutical company that's developing several obesity treatments. The price of the acquisition is $4.9 billion.
One of Metsera's drug candidates, MET-233i, can be taken less frequently than the Novo Nordisk and Lilly drugs, and has proven highly effective -- it helped patients in one study to lose 8.4% of their body weight in 36 days.
These weight loss drugs are big, and rapidly getting bigger. An investment in Pfizer today could pay off in a major way as this trend continues.
Should you invest $1,000 in Pfizer right now?
Before you buy stock in Pfizer, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $590,357!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,141,748!*
Now, it’s worth noting Stock Advisor’s total average return is 1,033% — a market-crushing outperformance compared to 193% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
*Stock Advisor returns as of October 27, 2025
Matthew Benjamin has positions in Novo Nordisk. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

What Is 1 of the Best Pharmaceutical Stocks to Buy Now?

The third-quarter 2025 reporting cycle for the Medical sector is about to pick up pace this week, as most firms are slated to share their earnings results over the next two weeks. The sector mainly comprises pharma/biotech and medical device companies. The earnings season for the drug and biotech sector kicked off around mid-October when bellwether Johnson & Johnson reported strong third-quarter results, beating estimates for earnings and sales. J&J consequently raised its sales expectations for 2025 to reflect a strong operational performance so far this year.
While most of the pharma bigwigs are slated to report their earnings results later this week, Roche posted solid growth in the first nine months of 2025 as high demand for key drugs like Phesgo (breast cancer), Xolair (food allergies), Hemlibra (hemophilia A), Vabysmo (severe eye diseases) and Ocrevus (multiple sclerosis) offset the decline in sales of legacy drugs. Consequently, Roche now expects higher earnings per share growth in 2025.
Per the Earnings Trends report, as of Oct. 22, 13.3% of the companies in the Medical sector — representing 26.8% of the sector’s market capitalization — reported quarterly earnings. Of these, 87.5% exceeded earnings estimates, while an equal share also topped revenue expectations. Earnings increased 7.4% year over year, while revenues increased 9.8%. Overall, third-quarter earnings of the Medical sector are expected to decrease 4.3%, while sales are projected to rise 8.1% from the year-ago quarter.
Eli Lilly LLY, Merck MRK, AbbVie ABBV, Bristol Myers BMY and Gilead Sciences GILD are all slated to release theirquarterly results this week. Let us examine how these biotech/pharma companies are likely to have performed in the soon-to-be-reported quarter.
Eli Lilly
Lilly’s performance has been mixed, with the company exceeding earnings expectations in two of the trailing four quarters and missing the same on the other two occasions. It delivered a four-quarter negative earnings surprise of 2.31%, on average. In the last reported quarter, LLY delivered an earnings surprise of 12.48%.
Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) have a good chance of delivering an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Lilly has an Earnings ESP of -0.66% and a Zacks Rank #3 at present. The Zacks Consensus Estimate for sales and earnings for the third quarter is pegged at $16.01 billion and $6.02 per share, respectively. You can see the complete list of today’s Zacks #1 Rank stocks here.
Lilly is expected to deliver another strong quarter, driven by robust demand for its blockbuster GLP-1 drugs (Mounjaro and Zepbound), improved supply, deeper U.S. market penetration and expanding international launches. Beyond its cardiometabolic portfolio, LLY’s oncology and immunology drugs, including Verzenio, Taltz, and newer launches like Omvoh, Ebglyss and Jaypirca, are also expected to have supported steady top-line expansion in the third quarter.
Lilly is scheduled to release its quarterly earnings results before the opening bell on Oct. 30.
Eli Lilly and Company Price and Consensus
Merck
Merck has an encouraging earnings track record. It beat earnings estimates in each of the last four quarters, delivering an average earnings surprise of 3.92%. In the last reported quarter, MRK beat earnings estimates by 5.97%.
Merck has an Earnings ESP of -0.09% and a Zacks Rank #3 at present. The Zacks Consensus Estimate for sales and earnings for the third quarter is pegged at $17.06 billion and $2.36 per share, respectively.
Merck’s top-line growth in the third quarter is likely to have been driven by higher sales of its blockbuster cancer drug Keytruda, attributable to additional indications and patient demand.
Merck is scheduled to release its quarterly earnings results before the opening bell on Oct. 30.
Merck & Co., Inc. Price and Consensus
AbbVie
AbbVie has an impeccable earnings track record to date. ABBV’s earnings beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 2.46%. In the last reported quarter, AbbVie’s earnings beat estimates by 2.77%.
For the quarter to be reported, AbbVie has an Earnings ESP of 0.00% and a Zacks Rank #4 (Sell) at present. The Zacks Consensus Estimate for sales and earnings for the third quarter is pegged at $15.59 billion and $1.80 per share, respectively.
AbbVie’s top line is expected to have been driven by robust sales of key drugs Rinvoq, Skyrizi, Venclexta and Vraylar, coupled with significant contributions from newer drugs, namely Ubrelvy, Epkinly, Qulipta and Vyalev.
ABBV is scheduled to report its quarterly earnings results on Oct. 31, before the opening bell.
AbbVie Inc. Price and Consensus
Bristol Myers
Bristol Myers has an excellent earnings track record. BMY’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 22.71%. In the last reported quarter, Bristol Myers’ earnings surpassed estimates by 36.45%.
Bristol Myers has an Earnings ESP of -1.03% and a Zacks Rank #3 at present. The Zacks Consensus Estimate for sales and earnings for the third quarter is pegged at $11.83 billion and $1.51 per share, respectively.
Bristol Myers’ revenues in the third quarter of 2025 are likely to have been positively impacted by an increase in growth portfolio sales. The growth portfolio primarily comprises Opdivo, Orencia, Yervoy, Reblozyl, Opdualag, Abecma, Zeposia, Breyanzi, Camzyos, Sotyku, Krazati and others. However, total quarterly revenues are likely to have been adversely affected by a decline in sales from the legacy portfolio, which includes Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane, among others.
Bristol Myers is slated to release its quarterly earnings results before the opening bell on Oct. 30.
Bristol Myers Squibb Company Price and Consensus
Gilead Sciences
Gilead has an encouraging earnings track record so far. It beat earnings estimates in three of the last four quarters, missing the mark on the remaining occasion, delivering an average surprise of 11.04%. In the last reported quarter, GILD beat earnings estimates by 3.08%.
For the third quarter of 2025, Gilead has an Earnings ESP of -1.34% and a Zacks Rank #3. The Zacks Consensus Estimate for sales and earnings for the third quarter is pegged at $7.46 billion and $2.15 per share, respectively.
Gilead’s flagship HIV therapies — Biktarvy and Descovy — are likely to have boosted the company’s top line. However, the company’s revenues are likely to have been impacted by the new Medicare Part D model, which increases manufacturer discount obligations during the initial coverage and catastrophic phases and offers additional discounts for people who qualify for the low-income subsidy program, a group significantly affected by HIV.
Gilead is slated to report its third-quarter 2025 earnings results on Oct. 30, after market close.
Gilead Sciences, Inc. Price and Consensus
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.
See "2nd Wave" AI stocks now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

What's in Store for These 5 Pharma Bigwigs This Earnings Season?

Key Points
Eli Lilly is one of the largest drug companies in the world.
The pharmaceutical giant's stock price is 15% below its 2024 high-water mark.
Lilly's valuation numbers tell an important story if you're thinking about buying the stock.
With a market cap of around $730 billion, Eli Lilly (NYSE: LLY) is one of the largest pharmaceutical companies on planet Earth. It has a strong position in the emerging niche of weight loss drugs, with patent protections that extend into the mid-2030s. And there's a solid pipeline of drugs coming up, too.
Lilly is a very well-positioned drugmaker. But don't rush out to buy it just yet. Here's why.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Even a good business can be a bad investment if you pay too much
Benjamin Graham is probably best known today for his book The Intelligent Investor. He's also known as a famed value investor, the father of fundamental analysis, and the man who helped train Warren Buffett, the legendary CEO of Berkshire Hathaway. Simply put, Graham is the reason why Buffett takes such care to buy good companies only when they look attractively priced.
One of Graham's maxims is that even a good business can be a bad investment if you overpay for it. Basically, a company's valuation matters, and you shouldn't ignore it. This is the key factor to consider when looking at Eli Lilly today.
Eli Lilly is a good business
Lilly is a pharmaceutical giant. It operates in a competitive industry that's highly technical. There's also the complication of patent protection on new drugs, which is provided for only a limited time. Every drug company has to balance investing in research and development against the patent cliffs it encounters as important patents expire.
Eli Lilly is no different from any of its peers in this regard. But it's particularly well positioned right now, while some of its peers are facing troubling patent cliffs in the next couple of years. Specifically, the company's weight loss drugs are not only in high demand, but they have patent protection until the mid-2030s. GLP-1 drugs Mounjaro and Zepbound are right at the center of what has been a huge growth engine for the pharma sector. That should help to power Lilly's performance for roughly the next decade.
That's great, but Wall Street is well aware of this fact. To start with, Eli Lilly's dividend yield is currently a slim 0.7%. That's well below the 1.2% of the S&P 500 index, and the 1.5% average yield for the overall drug sector. But, even more notable, Lilly's yield is near the lowest levels in the company's history. That hints very strongly that the stock is on the expensive side.
This view is backed up by more traditional valuation metrics. Eli Lilly's price-to-sales (P/S) ratio is around 14, versus a five-year average of 11.3. The company's price-to-earnings (P/E) ratio is near 54, compared to a longer-term average of 52.3. And the price-to-book (P/B) ratio is a touch over 40, versus a five-year average of just under 39.
To be fair, while the dividend yield hints at a very expensive stock, more traditional valuation metrics only suggest that the shares are modestly expensive. But either way you look at it, investors are not getting a low price when they buy Eli Lilly shares right now. Benjamin Graham probably wouldn't buy the stock today.
Make sure you're willing to pay the price
Lilly has, over the longer term, proven itself to be a well-run drugmaker. And it's positioned to take advantage of one of the most important trends in the pharmaceutical industry. But that good news looks like it's been priced into the stock.
Even though Eli Lilly has fallen around 15% from the highs it reached in 2024, most investors will probably be better off keeping this one on the wish list for now.
Should you invest $1,000 in Eli Lilly right now?
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $590,357!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,141,748!*
Now, it’s worth noting Stock Advisor’s total average return is 1,033% — a market-crushing outperformance compared to 193% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
*Stock Advisor returns as of October 27, 2025
Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Berkshire Hathaway. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Down 15%, Should You Buy the Dip on Eli Lilly?

Wall Street analysts expect Eli Lilly (LLY) to post quarterly earnings of $6.02 per share in its upcoming report, which indicates a year-over-year increase of 410.2%. Revenues are expected to be $16.01 billion, up 40% from the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.3% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
With that in mind, let's delve into the average projections of some Lilly metrics that are commonly tracked and projected by analysts on Wall Street.
The consensus among analysts is that 'Net Sales- Cyramza (Ramucirumab /IMC-1121B)- Total' will reach $237.79 million. The estimate suggests a change of +0.8% year over year.
Analysts predict that the 'Net Sales- Humulin' will reach $180.73 million. The estimate indicates a year-over-year change of -12.7%.
The average prediction of analysts places 'Net Sales- Humalog' at $512.59 million. The estimate points to a change of -4.1% from the year-ago quarter.
Analysts' assessment points toward 'Net Sales- Forteo' reaching $96.63 million. The estimate suggests a change of -18.2% year over year.
According to the collective judgment of analysts, 'Net Sales- Cyramza (Ramucirumab /IMC-1121B)- US' should come in at $107.96 million. The estimate suggests a change of +1.4% year over year.
Based on the collective assessment of analysts, 'Net Sales- International- Humalog' should arrive at $212.55 million. The estimate points to a change of +0.8% from the year-ago quarter.
Analysts expect 'Net Sales- International- Forteo' to come in at $40.97 million. The estimate indicates a year-over-year change of -11.7%.
The combined assessment of analysts suggests that 'Net Sales- Humulin- US' will likely reach $126.25 million. The estimate points to a change of -15.8% from the year-ago quarter.
The consensus estimate for 'Net Sales- US- Humalog' stands at $300.04 million. The estimate points to a change of -7.4% from the year-ago quarter.
Analysts forecast 'Net Sales- US- Forteo' to reach $55.66 million. The estimate points to a change of -22.4% from the year-ago quarter.
It is projected by analysts that the 'Geographic Revenue- United States' will reach $11.13 billion. The estimate suggests a change of +42.5% year over year.
The collective assessment of analysts points to an estimated 'Net Sales- Diabetes- Mounjaro - Outside U.S.' of $1.99 billion. The estimate suggests a change of +173.9% year over year.
View all Key Company Metrics for Lilly here>>>
Over the past month, Lilly shares have recorded returns of +13.9% versus the Zacks S&P 500 composite's +2.5% change. Based on its Zacks Rank #3 (Hold), LLY will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.
See "2nd Wave" AI stocks now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Eli Lilly and Company

Sign up and unlock all the capabilities of the AI-screener